E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
The medical condition being treated by this protocol is single or recurrent major depressive disorder (MDD), not responding to at least one adequate SSRI treatment, however, the patients being treated should be naïve to any atypical antipsychotic. |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.0 |
E.1.2 | Classification code | 10025453 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to assess the efficacy of Quetiapine fumarate augmentation on the overall depression status of patients with major depressive disorder who don’t respond to at least one acute treatment with a SSRI. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives are : - To assess the efficacy of Quetiapine fumarate augmentation on the psychological symptom patterns of patients with major depressive disorder - To assess the efficacy of Quetiapine fumarate augmentation on the functional disability - To assess the efficacy of Quetiapine fumarate augmentation on the global clinical impression of patients with major depressive disorder - To assess the safety and tolerability of Quetiapine fumarate in patients with major depressive disorder
|
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
For inclusion in the study all of the following criteria must be fulfilled on day 1: 1. Male and female patients, aged between 18 and 65 with a major depressive disorder not responding to at least one acute treatment with a SSRI and naïve to any atypical antipsychotic will be considered for entry into the study. 2. Provision of informed consent before initiating any study-related procedures 3. Female or male aged between 18 and 65 years who can read and write 4. Naïve to any atypical antipsychotic 5. A diagnosis of major depressive disorder, single or recurrent without psychotic features, according to the DSM-IV-R definition 6. Being treated for at least 6 weeks with a daily effective dose of an SSRI e.g. citalopram ≥ 20 mg, escitalopram ≥ 10 mg, fluoxetine ≥ 20 mg, fluvoxamine ≥ 100 mg, paroxetine ≥ 20 mg, sertraline ≥ 50 mg 7. MADRS score ≥ 25
|
|
E.4 | Principal exclusion criteria |
1. Patients with a history of bipolar I or II disorder as defined by DSM-IV-R 2. Diagnosis of psychotic major depression disorder according to the DSM-IV-R criteria 3. Substance of alcohol dependence at enrolment (except for caffeine or nicotine dependence) as defined by DSM-IV-R criteria 4. Opiates, amphetamine, barbiturate, cocaine, cannabis, or hallucinogen abuse by DSM-IV-R criteria 5. No or inadequate response to more than two different SSRIs given at the adequate dose during an adequate period of time 6. Use of any of the following CYP450 3A4 inhibitors in the 14 days preceding enrolment including but not limited to fluvoxamine, ketoconazole, itraconazole, fluconazole, erythromycin, clarithromoycin, troleandeomycin, indinavir, nelfinavir, ritonavir and saquinavir 7. Use of any of the following CYP450 3A4 inducers in the 14 days preceding the enrolment including but not limited to : phenytoin, carbamazepine, barbiturates, rifampin, St. John’s Wort, and flucocorticoids 8. Use of the SSRI fluvoxamine in the 14 days preceding the enrolment 9. Medical conditions that would affect absorption, distribution, metabolism or excretion of study treatment 10. Pregnancy, breast-feeding or planned pregnancy during the study. Fertile women not using a medically acceptable contraceptive. 11. Known or suspected hypersensitivity to the investigational product or excipiens 12. Planned in-patient hospitalization during the course of the study. 13. Any clinically significant abnormal finding at visit 1, which in the opinion of the investigator, may put the patient at risk because of his/her participation in the study. 14. Patients suffering from hyperthyroidism 15. In the opinion of the investigator, the patient is likely to be non-compliant with the study visit schedule or with the study procedures (e.g. illiterate, poor compliance, etc.) 16. Involvement in the planning and the conduct of the study (applies to both AstraZeneca staff or staff at the investigational site) 17. Previous enrolment in the present study. 18. Patients who in the opinion of the investigator, pose an imminent risk of suicide or danger to self or others. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is to see a general average decrease in MADRS score over 4 weeks of treatment with Quetiapine fumarate. Whereas response is defined as a reduction in MADRS score of 50 % or more and remission is defined as a MADRS score equal to or below 12.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of study is defined as database lock, which is the time point after which no changes are made to the database. Last subject last visit is planned end of April 2006. Estimated date of database lock is June 2006, which is 2 months after "Last Subject Last Visit". |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 11 |
E.8.9.1 | In the Member State concerned days | |